Moderna's shares rose by 2.9% in pre-market trading as they rebounded from a recent decline. This follows a significant rally triggered by positive Phase 3 trial results for its personalized mRNA cancer vaccine, intismeran autogene, which showed a reduction in melanoma recurrenc…
Pfizer's stock is receiving a BUY rating from analysts, with a price target of $32.36, indicating a potential upside of 15%. The company has shown strong revenue performance and p…
Despite a significant increase in Merck's stock price following strong Q2 earnings, an unusual volume of put options has been traded, suggesting investor concerns about potential…
Following Treasury Secretary Bessent's announcement to double bond buybacks, major stock indices experienced a rally, although futures are currently trading lower. Analysts have m…
Moderna's stock experienced a significant increase of more than 90% in premarket trading after the company announced positive results from a Phase 3 trial of its personalized mRNA…
The Dow Jones Industrial Average fell 343 points on August 6, marking a 0.63% decline and ending a six-session winning streak that had seen all major indices reach record highs. T…
Brighteon University is set to stream 'Vaccine Education for Mama Bears,' an educational series aimed at empowering parents to make informed vaccination decisions for their childr…
Mason Henderson, a 21-year-old diagnosed with a rare brain tumor, faced significant obstacles in obtaining treatment due to insurance coverage issues. Despite his doctors' recomme…
Merck, Amgen, and Johnson & Johnson are leveraging artificial intelligence to enhance drug discovery and improve healthcare outcomes. These companies have significantly outperform…